The CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) trial investigated the relationship between inflammation and atherosclerosis comparing canakinumab, an interleukin-1β (IL-1β) inhibitor, versus placebo. The gene discussed is IL1B; the disease is atherosclerosis.